GlassScriptPhysician profile
Anil Yadav
NPI 1245323468
$11,018.42
in general payments reported to CMS, 2019-2025
51 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,280 · 2020: $1,495 · 2021: $2,137 · 2022: $1,871 · 2023: $1,503 · 2024: $1,627 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,223 · Entertainment: $13.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,223.49 |
| Entertainment | $13.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,411.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,739.34 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $767.85 | 2019-2025 | Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $689.12 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $574.79 | 2019-2022 | |
| Glaxosmithkline, LLC. | $516.69 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $468.11 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Allergan, INC. | $340.13 | 2019-2022 | |
| Antares Pharma, INC. | $286.18 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Pfizer INC. | $267.18 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $246.64 | 2019-2025 | Trintellix, Glassia |
| Axsome Therapeutics, INC. | $232.00 | 2023-2025 | Auvelity, Symbravo |
| Otsuka America Pharmaceutical, INC. | $195.00 | 2019-2025 | Rexulti |
| Astellas Pharma US INC | $166.65 | 2024-2025 | Veozah |
| Galderma Laboratories, L.P. | $150.64 | 2021-2024 | Dysport |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Yadav listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.